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Abstract
The human trophoblast secretes endothelin-1 (ET-1) and expresses ET receptors. The present study tested whether the
transformed BeWo, JAR and JEG-3 choriocarcinoma cells : (1) secrete endothelin-1 (ET-1); (2) express both ET-A and ET-B
receptor subtypes; and (3) have the potential to allow for autologous regulation of ET-receptor proteins. The cells were
cultured for 24/48 h with or without 10% FCS and, in experiments on receptor regulation, with ET-1 (5^20 nM and 10 WM).
ET-1 secretion was measured by RIA and receptor levels by immunoblotting. All cell types secreted ET-1 albeit at different
levels and sensitivity to FCS. All cell lines expressed both ET-A (JEG-3sBeWo = JAR) and ET-B (JEG-3 = JARsBeWo)
receptor subtypes, which could be up- and downregulated depending on ET-1 concentration, culture time and FCS presence.
It is concluded that BeWo, JAR and JEG-3 choriocarcinoma cells secrete ET-1 and express both ET-A and ET-B receptor
subtypes. The receptor levels can be regulated by ET-1. This provides the molecular basis for an autocrine system with the
potential of autologous regulation of yet unidentified ET-1-induced functions. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Endothelin-1 (ET-1), ¢rst identi¢ed in 1988 [1], is a
polypeptide hormone, which belongs to a superfam-
ily of 21-amino acid peptides also including ET-2
and ET-3. ET-1 is a potent natural vasoconstrictor
and plays a central role in the vasomotor control of
blood vessels and elevation of blood pressure. How-
ever, over the past years it has been realized that ET-
1 also exerts a number of e¡ects in non-vascular
tissues. It has mitogenic and co-mitogenic e¡ects in
various cell types in vitro, e.g. endothelial cells, vas-
cular smooth muscle cells, cardiac myocytes, ¢bro-
blasts and glomerular mesangial cells [2^5] and even
stimulates chemokinesis [6]. Recently, a stimulating
action of ET-1 on cell invasion into extracellular ma-
trix has been identi¢ed in our laboratory [7].
ET-1 acts in both a paracrine and autocrine man-
ner [6,8]. Its e¡ects are mediated by binding to dis-
tinct cell surface receptors. Two receptor subtypes,
ET-A and ET-B, have been described in the human
[9] with di¡erent preferences for their ligands [10].
The ET-A receptor is selective for ET-1 and ET-2,
and binding to this subtype causes contraction and
proliferation [11^13]. The ET-B receptor binds all
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three isoforms with similar a⁄nity, thereby mediat-
ing vasodilatation [14] and stimulating invasion [15].
Both endothelin receptor subtypes have been cloned
from a human placental cDNA library and se-
quenced. They are 427 (ET-A) and 442 (ET-B) ami-
no acids in length, respectively [16,17]. The molecular
weights calculated from the deduced amino acid se-
quences are 48 625 Da [18] and 46 951 Da [19] for the
ET-A and ET-B receptor, respectively.
The levels of ET-A and ET-B receptors are regu-
lated by a variety of factors and also by ET-1 itself
[6,20^23], which in several cells causes downregula-
tion, predominantly of the ET-B receptor [24].
Recently, endothelin secretion as well as expres-
sion of both ET-A and ET-B receptor subtypes has
been found in a number of primary cancers, meta-
static sites and in carcinoma cells [25^31]. Therefore,
endothelins along with their receptors may form an
autocrine or paracrine network ultimately activating
several responses. These may be mediated by distinct
or both receptor subtypes. The best documented ex-
ample is the speci¢c ET-A receptor signalling of the
mitogenic ET-1 e¡ect in cancer cells [28,29].
Choriocarcinoma is a relatively rare malignant tu-
mor, which originates from the trophoblast of hu-
man placenta. Histologically, this tumor exclusively
consists of broad sheets of embryonic cytotropho-
blast forming the central portion of the tumor, and
of syncytiotrophoblast in the periphery of the tumor
[32]. Generally, the tumor produces large amounts of
human chorionic gonadotropin (hCG).
A number of choriocarcinoma cell lines have been
established. These replicating trophoblastic cells de-
rived from the malignant tumor or produced by viral
transformation of normal trophoblasts are appropri-
ate systems to test for consequences of malignant-
transformation. They express a stable phenotype in
vitro and most problems occurring in other experi-
mental model systems can be alleviated. Among
these BeWo, JAR and JEG-3 are the most widely
used.
The present study tested the hypothesis that
BeWo, JAR and JEG-3 choriocarcinoma cells: (1)
secrete endothelin-1 (ET-1); (2) express both ET-A
and ET-B receptor subtypes; and (3) have the poten-
tial to allow for autologous regulation of ET recep-
tors.
2. Materials and methods
2.1. Cell culture
BeWo, JAR and JEG-3 choriocarcinoma cells
were obtained from the American Type Culture Col-
lection (ATCC, Rockville, MD; BeWo, No. CCL-98,
passage 191; JAR, No. HTB-144, passage 722; JEG-
3, No. HTB-36, passage 124) and cultured in Dul-
becco’s modi¢ed Eagle’s medium (DMEM; Gibco,
Paisley, UK), supplemented with 10% (v/v) de¢ned
fetal calf serum (FCS; HyClone Laboratories, Lo-
gan, UT), 100 U/ml penicillin (Gibco) and 100 Wg/
ml streptomycin (Gibco) under a humidi¢ed 5%
CO2/95% air atmosphere at 37‡C. Cells were used
within passages seven and ¢fteen. Viability of the
cells was assessed by 0.05% (v/v) trypan blue (JRH
Biosciences, Crawley Down, Sussex, UK) dye exclu-
sion during a 2-min incubation and by measurement
of L-human chorionic gonadotropin (L-hCG) levels
(OPUS sandwich immunoassay; Behring Diagnos-
tics, Westwood, MA) secreted into the culture media.
When starting the experiments, the cells were cul-
tured in the presence or absence of FCS, and without
or with endothelin-1 (ET-1; Biogenesis, New Fields,
UK) at various concentrations (5, 10 and 20 nM and
20 WM), respectively. The purity of ET-1 was
checked by HPLC and mass spectrometry.
2.2. Protein content
The cell monolayers were washed with HBSS (Gib-
co) and cellular protein content was measured ac-
cording to the method of Lowry [33] using bovine
serum albumin as standard.
2.3. Endothelin-1 secretion
The levels of ET-1 secreted into the culture media
by each cell line were measured by a commercially
available radioimmunoassay using the Endothelin-
1,2 (high sensitivity) assay system with Amerlex-M
magnetic separation (Amersham, Little Chalfont,
UK) with the following performance characteristics:
sensitivity 0.5 fmol/ml ET-1, intra-assay coe⁄cient of
variation 6 5.8%, inter-assay coe⁄cient of variation
6 6.1%; cross-reactivity 100% with ET-1, 1305%
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with ET-2, 6 0.001% with ET-3 and 189% with Big-
ET-1.
2.4. SDS^polyacrylamide gel electrophoresis
(SDS^PAGE) and immunoblotting
Cells were washed with HBSS (Gibco), removed
from culture £asks with trypsin^EDTA solution
(Gibco) and solubilized by repeated pipetting in
Laemmli sample bu¡er (Sigma, Steinheim, Ger-
many). Insoluble material was removed by centrifu-
gation at 300Ug for about 7 min at 4‡C. Samples
were heated for 3 min in a boiling water bath. Equal
amounts of membrane protein, determined according
to Lowry [33], were subjected to SDS^PAGE on 8^
18% gradient gels (ExcelGel, Pharmacia, Uppsala,
Sweden) using SDS bu¡er strips (ExcelGel, Pharma-
cia) and samples were run for 150 min at 600 V/50
mA/30 W. Rainbow proteins (Amersham) were used
as molecular weight markers. Subsequently, proteins
were transferred onto nitrocellulose membranes
(Pharmacia) by semi-dry electroblotting in a bu¡er
containing 0.2 M glycine (Sigma), 25 mM Tris(hy-
droxymethyl)methylamine (Tris; Bio-Trade) and
20% (v/v) methanol for 45 min at 30 V/100 mA/6
W. Successful transfer was con¢rmed by Ponceau S
(Sigma) staining of the blots. The membranes were
blocked for 24 h with 5% (w/v) non-fat dry milk
(Bio-Rad, CA, USA) and 0.1% (v/v) Tween-20 (Sig-
ma) in 0.14 M Tris-bu¡ered saline, pH 7.4, at 4‡C.
The same solution was used as diluent for the anti-
bodies and for subsequent washings. The blotting
membranes were incubated for 60 min at room tem-
perature with sheep antisera against ET-A or ET-B
receptors (Alexis, San Diego, USA), diluted 1:150.
After three washes for 10 min each the blotting mem-
branes were further incubated with a rabbit anti-
sheep IgG horseradish peroxidase conjugate (South-
ern Biotechnology, Birmingham, USA), diluted
1:750, for 60 min at room temperature. After three
washes in 0.14 M Tris-bu¡ered saline, pH 7.4, the
immunolabeling was visualized using the chemilumi-
nescence based SuperSignal CL-HRP Substrate Sys-
tem (Pierce, Rockford, Illinois, USA) according to
the instructions of the manufacturer. Membranes
were exposed to High performance chemilumines-
cence ¢lm (Hyper¢lm ECL, Amersham) for 20 min,
which was subsequently quanti¢ed using the GelPrint
Workstation with Video Documentation System GP
2000i (MWG-Biotech, Ebersberg, Germany) and an-
alyzed by the ONE-Dscan program (Scanalytics, Bill-
erica, MA, USA).
In preliminary experiments, the coe⁄cient of var-
iation of immunoblotting was determined as þ 25%.
Therefore, any changes in band intensities 6 50%
were regarded as being insigni¢cant. All three ET-1
concentrations in the nM range produced similar re-
sults, which were, therefore, pooled.
2.5. Preadsorption of endothelin-antibodies
ET-A and ET-B antibodies, diluted 1:50 with 0.14
M Tris-bu¡ered saline, pH 7.4, were pre-adsorbed
with the corresponding oligopeptides, which had
been used for antibody generation (ET-A,
QEQNHNTERS SHK; ET-B, QTFEEKQSLE
EKQ; Pichem, Graz, Austria) in concentrations of
200, 20, 2, 0.2 and 0.02 Wg/ml and rocked for 24 h
at 4‡C. Thereafter the solutions were diluted 1:1 with
10% (w/v) non-fat dry milk (Bio-Rad) and 0.2% (v/v)
Tween-20 (Sigma) in 0.28 M Tris-bu¡ered saline, pH
7.4, to ¢nal concentrations of 1:200 Wg/ml (antibod-
ies) and 100, 10, 1, 0.1 and 0.01 Wg/ml (oligopep-
tides). These solutions were used for the primary in-
cubation of the blotting membrane. The subsequent
procedure was performed as described above.
2.6. Antisense oligonucleotides
JAR and JEG-3 were cultured for 96 h in DMEM
(Gibco) supplemented with 10% FCS (Hyclone) þ
2 WM phosphorothioate-modi¢ed antisense oligonu-
cleotides for the ET-A or ET-B receptor or with the
corresponding random sequence controls (Biognos-
tik, Go«ttingen, Germany), respectively, then har-
vested with cell scrapers, solubilized in Laemmli
Sample Bu¡er (Sigma), three times sonicated for 5 s
and heated in a boiling water bath for 5 min. Sam-
ples were then subjected to SDS^PAGE and immu-
noblotted as described above.
2.7. Cell cycle analysis
Cells were cultured in DMEM (Gibco) þ 10% FCS
(HyClone) for 12 and 24 h, respectively. Controls of
each cell line were obtained at t = 0. Cells were re-
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moved from culture £asks with trypsin^EDTA solu-
tion (Gibco). After centrifugation, the supernatant
was aspirated and the cells were subjected to cell
cycle analysis by £uorescence-activated pulse cyto-
photometry (FACS) on a PAS III cytophotometer
(Partec, Mu«nster, Germany) following a standard
protocol according to Goehde [34]. The percentage
of cells in each phase of the cell cycle was analyzed
by the Multicycle program (Phoenix Flow Systems,
San Diego, USA).
2.8. Statistical analysis
Results are presented as medians of three parallel
experiments. Inter-group comparisons for di¡erences
of the medians or means were statistically tested by
the Mann^Whitney Rank Sum Test or the unpaired
t-test, respectively, using SigmaStat 2.0 software
(Jandel, Erkrath, Germany). Signi¢cances were ac-
cepted at a level of 95% or more (P6 0.05).
3. Results
3.1. Characterization of cells
The choriocarcinoma cells of all three cell lines
rapidly attached and spread upon the coverslips.
They formed large, connecting clusters. During the
¢rst hour after seeding, few single cells showed ex-
tensions resembling ¢broblasts. Cells had a promi-
nent nucleus as well as various dense particles in
the cytoplasm. Vacuoles could be observed in periph-
eral regions of the cells. Cells formed a tight epithe-
lium, but no true syncytia were observed. Population
doubling time was 33^40 h for BeWo and JAR, re-
spectively, and 50^60 h for JEG-3 cells. Viability of
the cells was s 95% by trypan blue exclusion. Hu-
man CG was secreted by all three cell lines in the
order of BeWoIJEG-36 JAR. Levels of JEG-3
(269 þ 98 mIU/ml/106 cells) were 4^10-fold higher
than those of BeWo (48 þ 4 mIU/ml/106 cells), but
only 30^40% of those of JAR (1017 þ 195 mIU/ml/
106 cells), which reached even 20-fold higher levels
than BeWo. Overall, due to increased cell number,
hCG-levels were higher after 48 h of culture time
(BeWo, +120%; JAR, +30%; JEG-3, +40%) and in
cultures with FCS (BeWo 2^5-fold and JAR/JEG-3
2^4-fold higher levels).
3.2. Endothelin-1 secretion
All cell types secreted ET-1, albeit at di¡erent lev-
els and sensitivity to FCS. Levels in BeWo and JAR
Table 1
ET-1 levels (fmol/106 cells) secreted into culture medium by BeWo, JAR and JEG-3 choriocarcinoma cells after 24 h of incubation in
the absence and presence of FCS
Cell line ET-1 levels (fmol/106 cells) Relative changes by FCS
3FCS +FCS
BeWo 2.3 þ 0.46 3.3 þ 0.6 +43%
JAR 3.1 þ 0.56 3.7 þ 0.92 +19%
JEG-3 1.0 þ 0.15 6.7 þ 1.81* +570%
*P6 0.01 vs. 3FCS.
Fig. 1. (a) Western blot of BeWo cells with (P) and without (C)
pre-incubation of ET-A and ET-B antisera with the correspond-
ing oligopeptides in concentrations of 0.1 or 10 Wg/ml, respec-
tively. (b) Western blot of JAR cells after 96 h treatment with
phosphorothioate-modi¢ed antisense oligonucleotides for the
ET-A (Anti A) and ET-B (Anti B) receptor or with the corre-
sponding random sequence controls (rs) and untreated controls
(co).
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were 2 fmol ET-1/106 cells/24 h in the absence of
FCS without notable changes by FCS. ET-1 levels
in JEG-3 cells after 24 h of culture in FCS absence
were only 33^50% of BeWo and JAR (0.98 fmol ET-
1/106 cells/24 h), but JEG-3 was the only cell line
which pronouncedly (P6 0.01) responded to FCS
presence with a 5^7-fold increase of ET-1 levels (Ta-
ble 1).
3.3. ET-A and ET-B receptor levels
Immunoblotting produced bands with molecular
weights ranging between 20 and 97 kDa. Preadsorp-
tion of antisera with corresponding oligopeptides (0.1
Wg/ml for ET-A and 10 Wg/ml for ET-B) weakened
two bands at 33 and 50 kDa (Fig. 1a). Moreover,
when JAR and JEG-3 cells were incubated for 96 h
with 2 WM ET-A and ET-B receptor antisense oligo-
nucleotides, the density of the 33-kDa band de-
creased by 49 and 54% and the density of the 50-
kDa band was weakened by 20 and 73%, respectively
(Fig. 1b). Therefore, these two bands were consid-
ered speci¢c. All three choriocarcinoma cell lines expressed ET-
A and ET-B receptors with expression levels JEG-
3sBeWo = JAR and JEG-3 = JARsBeWo, respec-
tively. This ranking was independent of FCS pres-
ence. However, in all three cell lines, the addition
of FCS upregulated ET-A receptor levels by about
2.7-fold, but had no e¡ect on ET-B receptor levels
(Fig. 2).
Prolonged culture of the cells up to 48 h without
supplementation of ET-1 pronouncedly upregulated
ET-A receptors (BeWo/JAR) regardless of the pres-
ence or absence of FCS, whereas ET-B receptor lev-
els were downregulated, if changed at all (Fig. 3).
ET-receptor levels of all three cell lines responded
to ET-1, and FCS pronouncedly a¡ected the re-
sponse. BeWo cells were most responsive to ET-1
(in 71% of all experiments) as opposed to JAR and
JEG-3, in which ET-1 receptor levels were only
changed in 36% of all experiments. In the absence
of FCS, ET-1-induced changes in ET-receptor levels
were about twice as frequent as in the presence of
FCS (60 vs. 36%, respectively).
In FCS absence, both receptor subtypes responded
similarly to nM ET-1 doses depending on the cell
type and culture time: after 24 h, both ET-A and
ET-B receptor levels were downregulated in BeWo,
Fig. 2. In£uence of FCS on ET-A and ET-B receptor levels.
Western blotting of BeWo, JAR and JEG-3 cells cultured for
24 h without ET-1 in the absence (3) or presence (+) of 10%
(v/v) FCS. Representative example for three independent experi-
ments.
Fig. 3. In£uence of culture time on ET-A and ET-B receptor
levels in BeWo (b), JAR (F) and JEG-3 (R) cells (median of
three independent experiments). The cells were cultured for 48
h without ET-1 in the absence or presence of 10% (v/v) FCS.
The data are expressed as changes in ET-A and ET-B receptor
levels (determined by Western blotting) between 24 and 48 h
relative to those at 24 h ( = 0%). The shaded area denotes the
range in which changes are regarded insigni¢cant.
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but upregulated in JAR and JEG-3. Incubation with
ET-1 for further 24 h (t = 48 h) at nM concentrations
did not change the downregulation in BeWo (ET-A,
360%; ET-B, 370% of control). In JAR, the initial
upregulation after 24 h was only transient and no
longer present after 48 h. In JEG-3, small but oppo-
site changes in ET-A and ET-B vs. 24 h were found
(ET-A, +70%; ET-B, +40% of control) (Fig. 4). Both
receptor subtypes also responded to 10 WM ET-1
with an upregulation in BeWo (+100%) and JAR
(ET-A, +110%; ET-B, +190%), but in JEG-3, only
ET-A responded with a 50% downregulation, where-
as ET-B levels were unchanged (Fig. 4).
In FCS presence, nM ET-1 a¡ected ET receptors
only in BeWo and JEG-3, in which both receptor
subtypes were upregulated after 48 h (ET-A,
+120% and +70%; ET-B, +70% and +190%, respec-
tively). In cultures with 10 WM ET-1 only JEG-3
responded at all by a 90% downregulation of ET-
A, but not of ET-B, similar to results in FCS ab-
sence. In JAR cells, ET receptors did not respond
to ET-1 in the presence of FCS, regardless of the
culture time and ET-1 concentration (Fig. 5).
The in£uence of FCS is best exempli¢ed in a col-
lective analysis: in the absence of FCS, downregula-
tion was more frequent in the nM ET-1 range (60%),
whereas in the pharmacological range, 80% of re-
sponses were an upregulation. Addition of FCS to-
tally reverted these responses: at low ET-1 concen-
trations, upregulation occurred in 79% of all
responses; however, at the high ET-1 level, the cells
responded by downregulation only, if at all.
3.4. Cell cycle analysis
In order to test whether the di¡erences observed in
Fig. 4. E¡ect of ET-1 on ET-A and ET-B receptor levels in the
absence of FCS (median of three independent experiments).
BeWo, JAR and JEG-3 cells were cultured for 24 and 48 h
without or with nM (b) and WM (F) ET-1 doses. Changes in
ET-A and ET-B receptor levels (determined by Western blot-
ting) are expressed relative to the control levels of untreated
cells. The shaded area denotes the range in which changes are
regarded insigni¢cant. The 48-h values for the WM ET-1 con-
centrations were not determined.
Fig. 5. E¡ect of ET-1 on ET-A and ET-B receptor levels in the
presence of 10% (v/v) FCS (median of three independent experi-
ments). BeWo, JAR and JEG-3 cells were cultured for 24 and
48 h without or with nM (b) and WM (F) ET-1 doses. Changes
in ET-A and ET-B receptor levels (determined by Western blot-
ting) are expressed relative to the control levels of untreated
cells. The shaded area denotes the range in which changes are
regarded insigni¢cant. The 48-h values for the WM ET-1 con-
centrations were not determined.
Fig. 6. Proportion (median of three independent experiments)
of BeWo cells in the phases of the cell cycle (G0/G1, dotted; S,
open, G2/M, hatched bars) after 12 and 24 h of incubation in
the absence and presence of 10% (v/v) FCS, respectively. Con-
trol values were obtained at t = 0. *P6 0.01 vs. 3FCS.
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the presence and absence of FCS are due to di¡erent
proportions of cycling vs. non-cycling cells, cell cycle
analysis was performed using FACS.
In BeWo cells, 12 h of serum deprivation (i.e. cul-
ture without FCS) resulted in a 55^60% decrease
(P6 0.01) of the proportion of cells in the S-phase
concomitant with an increase of cells arrested in the
G0/G1-phase. These e¡ects were transient because
they were not observed after 24 h when the propor-
tion of cells in the S- and G0/G1-phase was similar
to 0 h (Fig. 6). Results for JAR cells were similar but
JEG-3 were una¡ected, i.e. the distribution of cells in
the phases of their cell-cycle was unchanged by se-
rum deprivation (not shown).
4. Discussion
4.1. Characterization of cells
Since culture conditions may a¡ect choriocarcino-
ma cell di¡erentiation in vitro [35], viability and en-
docrine activity of the investigated BeWo, JAR and
JEG-3 cell lines were extensively characterized and
validated in the present study. Choriocarcinoma cells
displayed no evidence of cell surface polarization.
Morphological features of the cultured cells are in
agreement with earlier data [36] and it was con¢rmed
on the basis of morphological criteria that even after
prolonged culture none of the three cell lines fused to
form true syncytia [35,37].
The observed di¡erence in hCG production among
the three cell lines might be due to the fact that the
JAR cell line has been directly established from a
trophoblastic tumor of the placenta [38], whereas
the BeWo and JEG-3 cell lines were derived from
tissue passed in the hamster cheek pouch [37^41].
Since production of hCG is the most important en-
docrine activity of choriocarcinoma [32], and, thus,
its hallmark, one may conclude that JAR cells more
closely resemble the original transformed phenotype
in choriocarcinoma than BeWo and JEG-3 cells. This
is also supported by the observation that tumors
resulting after transplantation of JAR cells show sim-
ilar characteristics to what has been described for
spontaneous choriocarcinoma [42]. This similarity
of JAR cells and choriocarcinoma might, at least in
part, explain why e¡ects of both ET-1 and FCS gen-
erally were smaller in BeWo and JEG-3 than in JAR
cells.
4.2. ET-1 secretion
An important question to be addressed in the
present study was whether the choriocarcinoma cells
secrete ET-1. The presence of ET receptors along
with the secretion of ET-1 would provide the molec-
ular basis for an autocrine regulatory loop for yet
unidenti¢ed ET-1-dependent choriocarcinoma cell
functions. Several other, but not all, tumor cell lines
secrete ET-1, foremost examples are breast cancer
cells, pancreatic carcinoma and colon carcinoma
[25]. This has prompted the notion of an auto- or
paracrine action of ET-1 in these human cancer cell
lines, and growth promotion was identi¢ed as the
corresponding ET-1 e¡ect [26^28].
All three choriocarcinoma cell lines secreted ET-1,
albeit at di¡erent levels and with varying response to
the presence of FCS. In general, ET-1 secretion of
BeWo and JAR was greater than that of JEG-3 in
the absence of FCS, whereas addition of FCS re-
sulted in the order JEG-3s JARsBeWo. Since se-
rum deprivation did not pronouncedly arrest the cells
in G0, especially not after 24 h, di¡erential ET-1
production/secretion of resting vs. cycling cells is un-
likely to account for these serum e¡ects. Rather se-
rum components, such as growth factors and cyto-
kines like insulin [43,58], or vasoactive substances,
such as prostaglandin [44], may stimulate ET-1 secre-
tion in JEG-3 cells. The absence of a serum e¡ect in
BeWo and JAR suggests a di¡erential susceptibility
to these serum components as opposed to JEG-3
cells. Whether transcriptional or translational factors
account for the cell-speci¢c di¡erences is unknown.
4.3. Speci¢city of antibodies
Published data about the molecular weight of the
ET receptors are rather contradictory and have led
to the suggestion of considerable tissue-speci¢c dif-
ferences. As yet, there are no data available for cho-
riocarcinoma or trophoblast cells. A variety of cross-
linking and gel ¢ltration studies were carried out
with placental tissue, which may be considered as
resembling choriocarcinoma. Molecular weights
ranged between 33 and 50 kDa [18,45,46], but ex-
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treme values of approximately 200 and 340 kDa have
also been found [46,47].
At the time of the experiments, the antisera used
were the only ones available and their speci¢city had
to be scrutinized. The most predominant bands for
both receptor subtypes corresponded to molecular
weights of 33 and 50 kDa. Their intensities were
weakened after pre-adsorption of the antisera with
the respective oligopeptides used for antiserum gen-
eration, and also after culture with ET-A and ET-B
receptor-speci¢c antisense oligonucleotides. There-
fore, it can be concluded that the 33- and 50-kDa
bands are the ET receptor-speci¢c bands in the cho-
riocarcinoma cell lines.
The 50-kDa band well corresponds to the calcu-
lated molecular weight of the primary amino acid
sequence and very likely represents the non-glycosy-
lated form of the receptors. Proteolytic cleavage of
this receptor form may account for the smaller 33-
kDa protein [48].
4.4. E¡ects of ET-1 on ET receptor protein levels
Previous investigations demonstrated the potency
of ET-1 to downregulate the number of its own re-
ceptor mRNA and protein. This has been reported
for a variety of vascular and non-vascular cells and
tissues [6,21^23]. According to the present study, the
choriocarcinoma cells BeWo, JAR and JEG-3 must
be added to this list.
It must be stressed that the present study did not
measure surface protein levels. Therefore, the terms
upregulation and and downregulation refer to
changes in this total pool of ET receptor proteins.
Heterologous upregulation of ET-1 receptors has
been observed in several cell types under a variety
of conditions. However, autologous upregulation is,
a novel ¢nding for the ET system, but not without
precedent in other ligand^receptor systems [49^52]. It
is a cell- and tissue-speci¢c phenomenon since up-
regulation was the predominant response in JEG-3
cells (80% of responses). ET-1 induced ET-receptor
upregulation may have escaped detection in other
studies because of much shorter times of exposure
to ET-1 or too low ET-1 concentrations. Whereas
both the ET-A and ET-B receptor levels were upreg-
ulated by ET-1 with similar frequency (52 vs. 48%),
ET-B receptor levels more often (P6 0.05) decreased
by ET-1 than ET-A (59 vs. 41%). This is in line with
the observation that ET-B receptors are more easily
down-regulated by prolonged ET-1 action than ET-
A receptors [24].
Two ranges of ET-1 concentrations were used
which di¡ered by three orders of magnitude, i.e.
nM (local concentrations in an autocrine/paracrine
system) and WM (pharmocological concentrations).
The lower ET-1 concentrations used in this study
(5^20 nM) are about three orders of magnitude
greater than circulating ET-1 levels (V1 pM). How-
ever, under the assumption of autocrine or paracrine
activity, the local concentrations of a cytokine within
a given tissue are much higher than its circulating
levels. The opposite responses of the cells to the
two di¡erent ranges of ET-1 concentrations clearly
demonstrate that future investigations into the auto-
crine or paracrine ET/ET-receptor system must use
very low concentrations of ET-1 corresponding to
those reached locally in these systems. Alternatively,
the autocrine e¡ects of secreted ET-1 can be studied
by inhibition of ET-1 production either by the metal-
loproteinase inhibitor phosphoramidon [21], or by
using ET-1-speci¢c antisense oligonucleotides [53].
Choriocarcinoma cells are sites of ET-1 production
and because ET-1 receptor proteins are expressed in
these cells, BeWo, JAR and JEG-3 choriocarcinoma
cells in vitro, as well as choriocarcinoma in vivo, may
be under autocrine in£uence by ET-1. The autolo-
gous regulation of ET-A and ET-B receptor levels
demonstrates that the autocrine ET/ET-receptor sys-
tem of the choriocarcinoma cells is under intrinsic
regulation. Because both ET-1 secretion and ET re-
ceptor expression may also be under control of a
variety of extrinsic factors, such as hypoxia/anoxia,
nitric oxide, growth factors, cytokines [43,58], vaso-
active substances [44,54] or steroids [8,55], which
may at least in part be derived from cells surround-
ing the choriocarcinoma, this system is likely part of
auto- and paracrine interactions between the chorio-
carcinoma and its surrounding non-transformed
cells. The strong in£uence of FCS in vitro on ET-1
secretion and regulation of ET-A and ET-B by ET-1
supports this hypothesis.
Although all cell types analyzed here have been
derived from the same type of tissue, i.e. choriocar-
cinoma, they responded di¡erently, suggesting that
any extrapolation from only one (chorio)carcinoma
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cell line to the in vivo phenotype must be made with
caution. This heterogeneity of response to an exoge-
nous stimulus observed in another study from this
laboratory [56] led us to employ here all three com-
monly used choriocarcinoma cell lines.
Collectively, the study clearly demonstrates the
presence of both components of an auto-/paracrine
system for ET-1 in all three choriocarcinoma cells
lines, i.e. secretion of ET-1 and expression of both
ET receptor subtypes. Although no cell-biological
correlates of the ET-1-induced changes in receptor
levels were measured, we suggest the existence of a
self-regulatory auto-/paracrine ET-1 system in cho-
riocarcinoma cell lines. This notion is supported by
data from our laboratory indicating that choriocar-
cinoma cell proliferation is under autoregulation of
the ET-1 system [57].
Acknowledgements
The work was supported by grants P10900 (to
G.D.) and P11550 (to M.C.) of the Austrian Science
Foundation, Vienna, and by grant 7259 (to M.C.),
Austrian National Bank, Vienna. The authors grate-
fully acknowledge the work of I. Andiel, E. Gras-
mugg, R. Michlmaier and E. Schmidt.
References
[1] M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, N.
Kobayashi, Y. Mitsue, Y. Yazaki, K. Goto, T. Masaki, A
novel potent vasoconstrictor peptide produced by vascular
endothelial cells, Nature 332 (1988) 411^414.
[2] H. Ito, Y. Hirata, S. Adachi, M. Tanaka, M. Tsujino, A.
Koike, A. Nogami, F. Marumo, M. Hiroe, Endothelin-1 is
an autocrine/paracrine factor in the mechanism of angioten-
sin II-induced hypertrophy in cultured rat cardiomyocytes,
J. Clin. Invest. 92 (1993) 398^403.
[3] H. Weber, M.L. Webb, R. Sera¢no, D.S. Taylor, S. More-
land, J. Norman, C.J. Molloy, Endothelin-1 and angioten-
sin-II stimulate delayed mitogenesis in cultured rat aortic
smooth muscle cells : evidence for common signaling mech-
anisms, Mol. Endocrinol. 8 (1994) 148^158.
[4] R. Tsuboi, C. Sato, C.M. Shi, T. Nakamura, T. Sakurai, H.
Ogawa, Endothelin-1 acts as an autocrine growth factor for
normal human keratinocytes, J. Cell Physiol. 159 (1995)
213^220.
[5] G.M. Rubanyi, M.A. Poloko¡, Endothelins: molecular biol-
ogy, biochemistry, pharmacology, physiology, and patho-
physiology, Pharmacol. Rev. 46 (1994) 315^415.
[6] J.J. Yohn, C. Smith, T. Stevens, J.G. Morelli, L.R. Shurnas,
S.J. Walchak, T.A. Ho¡man, K.K. Kelley, A. Escobedo-
Morse, M. Yanagisawa, M.A. Kane, M.R. Zamora, Autor-
egulation of endothelin-1 secretion by cultured human kera-
tinocytes via the endothelin B receptor, Biochim. Biophys.
Acta 1224 (1994) 454^458.
[7] M. Cervar, P. Puerstner, F. Kainer, G. Desoye, Endothelin-1
stimulates the proliferation and invasion of ¢rst trimester
trophoblast cells in vitro ^ a possible role in the etiology
of pre-eclampsia? J. Invest. Med. 44 (1996) 447^453.
[8] P. Roubert, I. Viossat, M.O. Lonchampt, M. Chapelat, J.
Schulz, P. Plas, V. Gillard-Roubert, P.E. Chabrier, P. Bra-
quet, Endothelin receptor regulation by endothelin synthesis
in vascular smooth muscle cells : e¡ects of dexamethasone
and phosphoramidon, J. Vasc. Res. 30 (1993) 139^144.
[9] T. Sakurai, M. Yanagisawa, T. Masaki, Molecular charac-
terization of endothelin receptors, Trends Pharmacol. Sci. 13
(1992) 103^108.
[10] T. Masaki, J.R. Vane, M.V. Vanhoutte, International union
of pharmacology nomenclature of endothelin receptors,
Pharmacol. Rev. 46 (1994) 137^142.
[11] Y. Wang, P.M. Rose, M.L. Webb, M.J. Dunn, Endothelins
stimulate mitogen activated protein kinase cascade through
either ETA or ETB, Am. J. Physiol. 267 (1994) C1130^
C1135.
[12] P.L. Smith, C.P. Lee, M. Pullen, E.H. Ohlstein, G. Beck,
E.P. Eddy, P. Nambi, Non peptide endothelin receptor an-
tagonists. IV. Identi¢cation of receptors in rabbit colonic
mucosa and smooth muscle and correlation with physiolog-
ical e¡ects, J. Pharmacol. Exp. Ther. 272 (1995) 1204^
1210.
[13] S.A. Douglas, L.M. Vickery-Clark, C. Louden, E.H. Ohl-
stein, Selective ETA receptor antagonism with BQ-123 is
insu⁄cient to inhibit angioplasty induced neointima forma-
tion in the rat, Cardiovasc. Res. 29 (1995) 641^646.
[14] T. Masaki, Possible role of endothelin in endothelial regu-
lation of vascular tone, Annu. Rev. Pharmacol. Toxicol. 35
(1995) 235^255.
[15] M. Cervar, F. Kainer, G. Desoye, Endothelin-1 stimulates
the invasion of ¢rst trimester trophoblast speci¢cally via the
A-type receptor, whereas its action on proliferation is medi-
ated by both receptor subtypes, J. Soc. Gyn. Invest. 4
(Suppl.) (1997) 94A.
[16] K. Hosoda, K. Nakao, H. Arai, S. Suga, Y. Ogawa, M.
Mukoyama, G. Shirakami, Y. Saito, S. Nakanishi, H. Im-
ura, Cloning and expression of human endothelin-1 receptor
cDNA, FEBS Lett. 287 (1991) 23^26.
[17] N.A. Elshourbagy, D.R. Korman, H.L. Wu, D.R. Sylvester,
J.L. Lee, P. Nuthalanganti, D.J. Bergsma, C.S. Kumar, P.
Nambi, Molecular characterization and regulation of the
human endothelin receptors, J. Biol. Chem. 268 (1993)
3873^3879.
[18] D.J. Hayzer, P.M. Rose, J.S. Lynch, M.L. Webb, B.K. Kien-
zle, E.C. Liu, E.A. Bogosian, E. Brinson, M.S. Runge, Clon-
BBADIS 61964 9-10-00
R. Mauschitz et al. / Biochimica et Biophysica Acta 1502 (2000) 224^234232
ing and expression of a human endothelin receptor: subtype
A, Am. J. Med. Sci. 304 (1992) 231^238.
[19] A. Sakamoto, M. Yanagisawa, T. Sakurai, Y. Takuwa, H.
Yanagisawa, T. Masaki, Cloning and functional expression
of human cDNA for the ET-B endothelin receptor, Biochem.
Biophys. Res. Commun. 178 (1991) 655^663.
[20] T. Sakurai, H. Morimoto, Y. Kasuya, Y. Takuwa, H. Na-
kauchi, T. Masaki, K. Goto, Level of ETB receptor mRNA
is down-regulated by endothelins through decreasing the in-
tracellular stability of mRNA molecules, Biochem. Biophys.
Res. Commun. 186 (1992) 342^347.
[21] M. Clozel, B.-M. Loe¥er, V. Breu, L. Hil¢ger, J.P. Maire,
B. Butscha, Downregulation of endothelin receptors by au-
tocrine production of endothelin-1, Am. J. Physiol. 265
(1993) C188^C192.
[22] S. Asada, Y. Kasuya, T. Sakurai, T. Masaki, K. Goto, En-
dothelin-1-induced downregulation of ETB receptor mRNA:
participation of cAMP, J. Cardiovasc. Pharmacol. 26 (Suppl.
3) (1995) S272^S275.
[23] J.C. Yu, A.P. Davenport, Regulation of endothelin receptor
expression in vascular smooth-muscle cells, J. Cardiovasc.
Pharmacol. 26 (Suppl. 3) (1995) S348^S350.
[24] S.A. Sudjarwo, M. Hori, T. Tanaka, Y. Matsuda, T. Okada,
H. Karaki, Subtypes of endothelin ETA and ETB receptors
mediating venous smooth muscle contraction, Biochem. Bio-
phys. Res. Commun. 200 (1994) 627^633.
[25] M. Kusuhara, K. Yamaguchi, K. Nagasaki, C. Hayashi, A.
Suzaki, S. Hori, S. Handa, Y. Nakamura, K. Abe, Produc-
tion of endothelin in human cancer cell lines, Clin. Cancer
Res. 50 (1990) 3257^3261.
[26] M. Shichiri, Y. Hirata, T. Nakajima, K. Ando, T. Imai, M.
Yanagisawa, T. Masaki, F. Marumo, Endothelin-1 is an
autocrine/paracrine growth factor for human cancer cell
lines, J. Clin. Invest. 87 (1991) 1867^1871.
[27] A. Bagnato, R. Tecce, V. Di Castro, K.J. Catt, Activation of
mitogenic signaling by endothelin-1 in ovarian carcinoma
cells, Cancer Res. 57 (1997) 1306^1311.
[28] A. Bagnato, D. Salani, V. Di Castro, J.R. Wu-Wong, R.
Tecce, M.R. Nicotra, A. Venuti, P.G. Natali, Expression
of endothelin 1 and endothelin A receptor in ovarian carci-
noma: evidence for an autocrine role in tumor growth, Can-
cer Res. 59 (1999) 720^727.
[29] J.B. Nelson, K. Chan-Tack, S.P. Hedican, S.R. Magnuson,
T.J. Opgenorth, G.S. Bova, J.W. Simons, Endothelin-1 pro-
duction and decreased endothelin B receptor expression in
advanced prostate cancer, Cancer Res. 56 (1996) 663^668.
[30] S. Moraitis, W.R. Miller, J.F. Smyth, S.P. Langdon, Para-
crine regulation of ovarian cancer by endothelin, Eur. J.
Cancer 35 (1999) 1381^1387.
[31] K.V. Patel, H.G. Sheth, M.P. Schrey, Stimulation or endo-
thelin-1 secretion by human breast cancer cells through pro-
tein kinase A activation: a possible novel paracrine loop
involving breast ¢broblast-derived prostaglandin E2, Mol.
Cell. Endocrinol. 126 (1997) 143^151.
[32] K. Benirschke, P. Kaufmann, Choriocarcinoma, in: K. Be-
nirschke, P. Kaufmann (Eds.), Pathology of the Human Pla-
centa, 3rd edn., Springer Verlag, New York, 1995, pp. 686^
708.
[33] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall,
Protein measurement with the Folin phenol reagent, J. Biol.
Chem. 193 (1951) 265^275.
[34] W. Goehde, J. Schuhmann, J. Zante, The use of DAPI in
pulse cytophotometry, in: D. Lutz (Ed.), Pulse Cytophotom-
etry, European Press, Gent, 1978, pp. 229^232.
[35] A.M. Mitchell, A.S. Yap, E.J. Payne, S.W. Manley, R.H.
Mortimer, Characterization of cell polarity and epithelial
junctions in the choriocarcinoma cell line JAR, Placenta 16
(1995) 31^39.
[36] R.S. Tuan, C.J. Moore, J.W. Brittingham, J.J. Kirwin, R.E.
Akins, M. Wong, In vitro study of placental trophoblast
calcium uptake using JEG-3 human choriocarcinoma cells,
J. Cell Sci. 98 (1991) 333^342.
[37] P.O. Kohler, W.E. Bridson, J.M. Hammond, B. Weintraub,
M.A. Kirschner, D.H. van Thiel, Clonal lines of human
choriocarcinoma cells in culture, Acta Endocrinol. 153
(Suppl.) (1971) 137^153.
[38] R.A. Pattillo, R.O. Hussa, R. Bernstein, E. Delfs, The Jar
cell line. Continous lines of human choriocarcinoma, In Vi-
tro 6 (1971) 398.
[39] R. Hertz, Choriocarcinoma of women maintained in serial
passage in hamster and rat, Proc. Soc. Exp. Biol. 102 (1959)
77^81.
[40] R.A. Pattillo, G.O. Gey, The establishment of a cell line of
human hormone-synthesizing trophoblastic cells in vitro,
Cancer Res. 28 (1968) 1231^1236.
[41] P.O. Kohler, W.E. Bridson, Isolation of hormone-producing
clonal lines of human choriocarcinoma, J. Clin. Endocrinol.
Metabol. 32 (1971) 683^687.
[42] S.L. Vaden, R.L. Page, B.P. Peters, J.M. Cline, J.E. Riviere,
Development and characterization of an isolated and per-
fused tumor skin preparation for evaluation of drug dispo-
sition, Cancer Res. 53 (1993) 101^105.
[43] E.M. Redmond, P.A. Cahill, R. Hodges, S. Zhang, J.V.
Sitzmann, Regulation of endothelin receptors by nitric oxide
in cultured rat vascular smooth muscle cells, J. Cell Physiol.
166 (1996) 469^479.
[44] A. Mallat, A.M. Preaux, C. Serradeil-Le-Gal, D. Raufaste,
C. Gallois, D.A. Brenner, C. Bradham, J. Maclouf, V. Iour-
genko, L. Fouassier, C. Dhumeaux, P. Mavier, S. Lotersz-
tajn, Growth inhibitory properties of endothelin-1 inacti-
vated human hepatic stellate cells : a cyclic adenosine
monophosphate-mediated pathway. Inhibition of both extra-
cellular signal-regulated kinase and c-Jun kinase and up-
regulation of endothelin B receptors, J. Clin. Invest. 98
(1996) 2771^2778.
[45] S. Nakajo, M. Sugiura, R.M. Snajdar, F.H. Boehm, T. In-
agami, Solubilization and identi¢cation of human placental
endothelin receptor, Biochem. Biophys. Res. Commun. 164
(1989) 205^211.
[46] B. Kalina, B.M. Loe¥er, Crosslinking analysis of an endo-
thelin receptor protein from human placenta, Biochem. Int.
27 (1992) 735^744.
BBADIS 61964 9-10-00
R. Mauschitz et al. / Biochimica et Biophysica Acta 1502 (2000) 224^234 233
[47] S. Nakajo, M. Sugiura, T. Inagami, Native form of endo-
thelin receptor in human placental membranes, Biochem.
Biophys. Res. Commun. 167 (1990) 280^286.
[48] N. Akiyama, O. Hiraoka, Y. Fujii, H. Terashima, M. Satoh,
K. Wada, Y. Furuichi, Biotin derivates of endothelin: uti-
lization for a⁄nity puri¢cation of endothelin receptor, Pro-
tein Expr. Purif. 3 (1992) 427^433.
[49] J. Iwaz, S. Lafont, G. Cordier, J.P. Revillard, Elevation of
3P5P cyclic adenosine monophosphate alters CD3 and CD25
antigens expression in activated T lymphocytes, J. Clin. Lab.
Immunol. 29 (1989) 85^89.
[50] U. Trefzer, M. Brockhaus, H. Loetscher, F. Parlow, A. Bud-
nik, M. Grewe, H. Christoph, A. Kapp, E. Schoepf, T.A.
Luger, J. Krutmann, The 55-kD tumor necrosis factor re-
ceptor on human keratinocytes is regulated by tumor ne-
crosis factor-alpha and by ultraviolet B radiation, J. Clin.
Invest. 92 (1993) 462^470.
[51] D.S. Skundric, B. Bealmear, R.P. Lisak, Induced upregula-
tion of IL-1, IL-1RA and IL-1R type I gene expression by
Schwann cells, J. Neuroimmunol. 74 (1997) 9^18.
[52] A. Menke, I. Geerling, K. Giehl, R. Vogelmann, M. Reins-
hagen, G. Adler, Transforming growth factor-beta-induced
upregulation of transforming growth factor-beta receptor
expression in pancreatic regeneration, Biochim. Biophys.
Acta 1449 (1999) 178^185.
[53] R. Schlingensiepen, W. Brysch, K.-H. Schlingensiepen,
(Eds.), Antisense ^ From Technology to Therapy. Blackwell
Science, Berlin, 1997.
[54] S. Eguchi, Y. Hirata, T. Imai, F.C. Marumo, C-type natriu-
retic peptide upregulates vascular endothelin type B recep-
tors, Hypertension 23 (1994) 936^940.
[55] P. Nambi, H.L. Wu, D. Lipshutz, U. Prabhakar, Identi¢ca-
tion and characterization of endothelin receptors on rat os-
teoblastic osteosarcoma cells : down-regulation by 1,25-dihy-
droxy-vitamin D3, Mol. Pharmacol. 47 (1995) 266^271.
[56] T. Hahn, S. Barth, W. Hofmann, O. Reich, I. Lang, G.
Desoye, Hyperglycemia regulates the glucose-transport sys-
tem of clonal choriocarcinoma cells in vitro. A potential
molecular mechanism contributing to the adjunct e¡ect of
glucose in tumor therapy, Int. J. Cancer 78 (1998) 353^
360.
[57] R. Mauschitz, M. Cervar, G. Desoye, Endothelin-1 stimula-
tion of proliferation is mediated by di¡erent receptor sub-
types in BeWo, JAR and JEG-3 choriocarcinoma cells,
J. Soc. Gyn. Invest. 6 (1999) 218A.
[58] G. LeBrun, P. Aubin, H. Soliman, F. Ropiquet, J.M. Vil-
lette, P. Berthou, C. Creminon, O. Cussenot, J. Fiet, Up-
regulation of endothelin 1 and its precursor by IL-1 beta,
TNF-alpha, and TGF-beta in the PC3 human prostate can-
cer cell line, Cytokine 11 (1999) 157^162.
BBADIS 61964 9-10-00
R. Mauschitz et al. / Biochimica et Biophysica Acta 1502 (2000) 224^234234
